Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine

Dermatology

Volumn 206, Issue 4, 2003, Pages 330-333

  Corazza, M ^a   Zampino, M R ^a   Montanari, A ^a   Altieri, E ^a   Virgili, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cyclosporine; Lymphoma; Psoriasis

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DITHRANOL; DOXORUBICIN; ETRETINATE; METHOTREXATE; PREDNISONE; TAR; VINCRISTINE;

ADULT; ARTICLE; ASTHENIA; BLOOD ANALYSIS; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IMMUNOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MEDICAL LITERATURE; OBSERVATION; POOR GENERAL CONDITION; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PUVA; REMISSION; SKIN BIOPSY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIGENS, CD30; CYCLOSPORINE; ETRETINATE; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOLYTIC AGENTS; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; PSORIASIS; RISK FACTORS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038316383     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069946     Document Type: Article

References (21)

1. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G: Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-475.
2. Sheil AG, Disney AP, Matthew TH, Livingston BE, Keogh AM: Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc 1997;29:825-827.
3. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B: Incidence and consequences of posttransplantation lymphoproliferative disorders. J Nephrol 1997;10:136-145.
4. Penn I: Cancers following cyclosporine therapy. Transplantation 1987;43:32-35.
5. Stockfleth E, Ulrich C, Meyer T, Christophers E: Epithelial malignancies in organ transplant patients: Clinical presentation and new methods of treatment. Recent Results Cancers Res 2002;160:251-258.
6. Cockburn ITR, Krupp P: The risk of neoplasm in patients treated with cyclosporine A. J Autoimmun 1989;2:723-731.
7. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI: The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26:836-840.
8. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-192.
9. Dantal J, Hourmant M, Cantarovitch D, Giral M, Blancho G, Dreno B, Soulillou JP: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628.
10. Paul C, Hornig F: Risk of malignancy associated with cyclosporin use in psoriasis. Dermatology 1999;198:320.
11. Krupp P, Monka C: Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990;122(suppl 36):47-56.
12. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L: Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-629.
13. Sivaraman P, Lye WC: Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed Pharmacother 2001;55:366-368.
14. Koo J, Lebwohl M: Letter to the editor. J Am Acad Dermatol 1999;40:1016.
15. Lamarque V, Monka C, Commare MC, Krupp P: Risk of malignancies in patients treated with Sandimmun® for autoimmune diseases; in Touraine JL, Traeger J, Betuel H (eds): Cancer in Transplantation: Prevention and Treatment. Dordrecht, Kluwer Academic, 1996, pp 141-148.
16. Cliff S, Pettengell R, Gharge S, Marsden RA: B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis. Br J Dermatol 1999;140:749-782.
17. Pielop JA, Jones D, Duvic M: Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol 2001;40:505-511.
18. Bekkenk MW, Geelen FAMJ, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJLM, Willemze R: Primary and secondary cutaneous CD30+ lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-3661.
19. De Coteau JF, Butmarc JR, Kinney MC, Kadin ME: The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large cell lymphoma of nodal origin. Blood 1996;87:3437-3441.
20. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJLM: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-371.
21. Starzl TE, Porter KA, Iwatsuki S, Rosenthal JT, Shaw BW Jr, Atchinson RW, Nalesnik MA, Ho M, Griffith BP, Hakala TR, Hardesty RL, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984;1:583-587.